Olink®

Olink® Reveal

# Proteomics, Unplugged

Powerful NGS-based proteomics—
effortlessly uncover meaningful insights

# Unlimited insights, Untapped potential

## Genomics + Proteomics: The Ultimate Partnership for Discovery

Proteomics takes the success of genomics further, offering dynamic, real-time insights into human biology and its changes—key for advancing precision medicine. Proteins bridge the gap between genotype and phenotype, while responding to the environment.




## Unlocking the Power of Proteomics at Scale

Olink has been chosen to analyze 600,000 samples in the UK Biobank (UKB) Pharma Proteomics Project, the world's largest human proteogenomics study.

"To date, the scientific community has invested substantially in genomics for the advancement of precision medicine. However, to identify the right drug for the right patient at the right time, we must move beyond genomics alone. This dataset will help paint a much more nuanced and detailed picture of how the human genome and proteins circulating in the blood influence human health and disease – enabling biomedical researchers to identify new biological associations, find new drug targets and build blood-based diagnostics."

Dr Chris Whelan, Director, Neuroscience, Data Science & Digital Health, Janssen Research & Development, LLC, a Johnson & Johnson Company, Pharma Proteomics Project Lead.[2]

1 - https://www.nature.com/articles/s41586-023-06592-6
2 - https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news

## UKB Pilot Outcomes[1]

- Identified pathways for drug targets
- Improved disease prediction scores
- >14,000 protein QTLs identified
- 100s peer reviewed studies

"As a genomics lab, it's important to leverage NGS-based proteomics, using a method that can work across a wide range of sample matrices with tools we already have in the lab."

Professor Chris Mason, Weill Cornell Medicine, NY

# Powerful Content, Actionable Insights

## Curated Content That Unlocks New Discoveries

Olink Reveal provides broad proteome coverage and deep profiling of inflammation and immune response.

### Broad proteome coverage

100% top level pathways and 64% of all pathways in Reactome[1]

1 - reactome.org

### Deep profiling of inflammation

537 inflammation proteins covering 96% of immune response pathways in Reactome[2]

2 - Reactome, Open Targets and Gene Ontology

### Curated library

~1,000 proteins, robustly detectable markers, with high proportion of *cis*-pQTLs for proteogenomics associations[3]

3 - PMID: 37794186, 39316441, 37794188


Olink Reveal covers all major pathways on level 0 and 64% of all levels from 0-12. This remains close to Olink Explore HT coverage, which targets 5 times more proteins.




"The number of proteins and breadth of pathways covered enabled us to identify proteins that may differentiate how leukemia patients respond differently to various BTK inhibitors over time. Due to its affordable cost, it would enable groups to scale testing across a large number of subjects and timepoints."

Professor Edvard Smith, Karolinska Institute




Volcano plots represent typical results obtained with Olink Reveal with pink markers denoting significant (adjusted p<0.05) and grey markers denoting non-significant

"Olink Reveal enabled us to identify biomarkers relevant for prediabetes that correlate with clinical data in our biobank samples."

Professor Karol Kaminski , Medical University Bialystok

# Trusted Technology, Demonstrated Results

## PEA Technology: Trusted for Precision and Reliability

Olink Reveal leverages the power of Olink's Proximity Extension Assay (PEA) technology, demonstrated through more than 2,300 publications.




Antibody pairs, labeled with DNA oligonucleotides, bind target antigens in solution




Oligonucleotides that are brought into proximity hybridize and are extended by a DNA polymerase



This newly created double stranded DNA barcode is amplified by PCR, ready for readout by NGS

## Setting the Standard for Proteomics Validation

Every assay is lab validated by our comprehensive 3-step, 15-factor assay validation process. The Olink Reveal library is enriched for proteins that are genetically validated.



# Olink Reveal Performance Specifications

- High Sensitivity: Detects as low as fg/ml
- Broad Compatibility: Validated in plasma and serum; compatible with various other matrices
- High Precision:
  Intra-plate CVs: 8.1%
  Inter-plate CVs: 4.8%
  Inter-site CVs: 6.3%
- Robust Marker Detection: Reliable performance across a wide range of biological markers
- Biological Detectability Range: 86-100%
- NGS Platform Compatibility: Supports multiple platforms, including NovaSeq X, NovaSeq 6000, NextSeq 2000, and more
- Reproducibility: High concordance with other Olink products based on overlapping content (R=0.95 Olink Explore HT, R=0.94 Olink Explore 3072, R=0.90 Olink Target 96 Inflammation) and high concordance between sites (R= 0.96-0.98)

Contact us to start your proteomics journey today with Olink Reveal or any of our other proteomics solutions at www.olink.com/reveal



1586, v1.3, 2025-08-12